Lantheus Holdings Inc. (NASDAQ:LNTH) saw an uptick in trading volume on Monday . 788,984 shares were traded during trading, an increase of 157% from the previous session’s volume of 306,508 shares.The stock last traded at $7.70 and had previously closed at $6.45.

A number of brokerages have issued reports on LNTH. Zacks Investment Research upgraded Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $7.00 price target on the stock in a research report on Monday, August 8th. Jefferies Group reiterated a “buy” rating on shares of Lantheus Holdings in a research report on Friday, August 5th. Finally, Credit Suisse Group AG set a $4.00 price target on Lantheus Holdings and gave the stock a “hold” rating in a research report on Friday, August 5th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Lantheus Holdings currently has a consensus rating of “Buy” and a consensus price target of $5.80.

The company’s 50-day moving average price is $4.64 and its 200 day moving average price is $2.77. The stock has a market capitalization of $230.33 million and a price-to-earnings ratio of 8.56.

Lantheus Holdings (NASDAQ:LNTH) last posted its earnings results on Thursday, August 4th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.18. The company earned $78 million during the quarter, compared to analysts’ expectations of $72.66 million. Equities analysts expect that Lantheus Holdings Inc. will post $0.48 EPS for the current fiscal year.

Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.